<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Aptevo Therapeutics Inc.

    verified_userVerify Profile
    Companies » Health Care » Health Care Equipment & Services » Biotechnology

    About Aptevo Therapeutics Inc.

    Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Marvin L. White
    • FOUNDED
      2016
    • EMPLOYEES
      101-250
    • SECTOR
      Health Care Equipment & Services
    • SUBSECTOR
      Biotechnology

    Company Tags

    No articles found.

    Viela Bio, Inc.

    Viela Bio, Inc.

    Viela is dedicated to the development and commercialization of novel, life-changin...

    Viela is dedicated to the development and comme...

    Filing Type:    PU
    Syndax Pharmaceuticals, Inc.

    Syndax Pharmaceuticals, Inc.

    Syndax Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on ...

    Syndax Pharmaceuticals, Inc. is a late-stage bi...

    Filing Type:    PU
    Gamida Cell Ltd.

    Gamida Cell Ltd.

    Gamida Cell is a clinical-stage biopharmaceutical company committed to developing ...

    Gamida Cell is a clinical-stage biopharmaceutic...

    Filing Type:    PU
    ViewRay, Inc.

    ViewRay, Inc.

    ViewRayÂŽ Inc., (NASDAQ:VRAY), designs, manufactures and markets MRIdianÂŽ the wor...

    ViewRayÂŽ Inc., (NASDAQ:VRAY), designs, manufac...

    Filing Type:    PU
    Intellia Therapeutics, Inc.

    Intellia Therapeutics, Inc.

    Intellia Therapeutics is a leading genome editing company focused on developing cu...

    Intellia Therapeutics is a leading genome editi...

    Filing Type:    PU
    Genetic Technologies Ltd

    Genetic Technologies Ltd

    Genetic Technologies is a leader in the development of genetic technology. Our tes...

    Genetic Technologies is a leader in the develop...

    Filing Type:    PU
    Immuron Limited

    Immuron Limited

    Immuron Ltd is a publicly listed Australian biopharmaceutical company focused on o...

    Immuron Ltd is a publicly listed Australian bio...

    Filing Type:    PU
    Midatech Pharma PLC

    Midatech Pharma PLC

    Midatech is an international specialty pharmaceutical company focused on the devel...

    Midatech is an international specialty pharmace...

    Filing Type:    PU
    Replimune Group, Inc.

    Replimune Group, Inc.

    Cancer is one of the most difficult diseases to treat. It is constantly changing, ...

    Cancer is one of the most difficult diseases to...

    Filing Type:    PU
    Kezar Life Sciences, Inc.

    Kezar Life Sciences, Inc.

    Based in South San Francisco, we are a clinical-stage biotechnology company commit...

    Based in South San Francisco, we are a clinical...

    Filing Type:    PU
    LifeBridge 10000, LLC

    LifeBridge 10000, LLC

    LifeBridge 10000, LLC specializes in extending and improving the quality of life f...

    LifeBridge 10000, LLC specializes in extending ...

    Amount Raised:    $23,091.00
    Fundraising Status:    EC
    Filing Type:    CF
    Celyad SA

    Celyad SA

    Celyad is a biopharmaceutical company, specialized in CAR-T cell therapy, that is ...

    Celyad is a biopharmaceutical company, speciali...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.